Switch theme
Sign up to access all valuation multiples
Lotus Pharmaceutical Co Ltd is engaged in the healthcare sector. The only reportable segment of the company is the Pharmaceuticals business segment, which engages mainly in the research and development, manufacturing and sales of pharmaceutical products. It has a geographic presence in the United States, Malta, Taiwan, and Others.
1966
750
LTM Revenue $574M
LTM EBITDA $235M
$2.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Lotus Pharmaceutical has a last 12-month revenue of $574M and a last 12-month EBITDA of $235M.
In the most recent fiscal year, Lotus Pharmaceutical achieved revenue of $561M and an EBITDA of $248M.
Lotus Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Lotus Pharmaceutical valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $512M | $561M | XXX | XXX | XXX |
| Gross Profit | $236M | $283M | XXX | XXX | XXX |
| Gross Margin | 46% | 50% | XXX | XXX | XXX |
| EBITDA | $207M | $248M | XXX | XXX | XXX |
| EBITDA Margin | 41% | 44% | XXX | XXX | XXX |
| Net Profit | $91.2M | $124M | XXX | XXX | XXX |
| Net Margin | 18% | 22% | XXX | XXX | XXX |
| Net Debt | $206M | $289M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Lotus Pharmaceutical's stock price is TWD 218 (or $7).
Lotus Pharmaceutical has current market cap of TWD 57.8B (or $1.7B), and EV of TWD 65.5B (or $2.0B).
See Lotus Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.0B | $1.7B | XXX | XXX | XXX | XXX | $0.60 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Lotus Pharmaceutical has market cap of $1.7B and EV of $2.0B.
Lotus Pharmaceutical's trades at 3.4x LTM EV/Revenue multiple, and 8.4x LTM EBITDA.
Analysts estimate Lotus Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Lotus Pharmaceutical and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.0B | XXX | XXX | XXX |
| EV/Revenue | 3.5x | XXX | XXX | XXX |
| EV/EBITDA | 8.0x | XXX | XXX | XXX |
| P/E | 11.4x | XXX | XXX | XXX |
| P/E/Growth | 3.0x | XXX | XXX | XXX |
| EV/FCF | 14.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpLotus Pharmaceutical's NTM/LTM revenue growth is 8%
Lotus Pharmaceutical's revenue per employee for the last fiscal year averaged $0.7M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Lotus Pharmaceutical's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Lotus Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Lotus Pharmaceutical and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 44% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 20% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 52% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.7M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 14% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 26% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lotus Pharmaceutical acquired XXX companies to date.
Last acquisition by Lotus Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Lotus Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Lotus Pharmaceutical founded? | Lotus Pharmaceutical was founded in 1966. |
| Where is Lotus Pharmaceutical headquartered? | Lotus Pharmaceutical is headquartered in Taiwan. |
| How many employees does Lotus Pharmaceutical have? | As of today, Lotus Pharmaceutical has 750 employees. |
| Who is the CEO of Lotus Pharmaceutical? | Lotus Pharmaceutical's CEO is Mr. Petar Antonov Vazharov. |
| Is Lotus Pharmaceutical publicy listed? | Yes, Lotus Pharmaceutical is a public company listed on TAI. |
| What is the stock symbol of Lotus Pharmaceutical? | Lotus Pharmaceutical trades under 1795 ticker. |
| When did Lotus Pharmaceutical go public? | Lotus Pharmaceutical went public in 2010. |
| Who are competitors of Lotus Pharmaceutical? | Similar companies to Lotus Pharmaceutical include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Lotus Pharmaceutical? | Lotus Pharmaceutical's current market cap is $1.7B |
| What is the current revenue of Lotus Pharmaceutical? | Lotus Pharmaceutical's last 12-month revenue is $574M. |
| What is the current EBITDA of Lotus Pharmaceutical? | Lotus Pharmaceutical's last 12-month EBITDA is $235M. |
| What is the current EV/Revenue multiple of Lotus Pharmaceutical? | Current revenue multiple of Lotus Pharmaceutical is 3.4x. |
| What is the current EV/EBITDA multiple of Lotus Pharmaceutical? | Current EBITDA multiple of Lotus Pharmaceutical is 8.4x. |
| What is the current revenue growth of Lotus Pharmaceutical? | Lotus Pharmaceutical revenue growth between 2023 and 2024 was 10%. |
| Is Lotus Pharmaceutical profitable? | Yes, Lotus Pharmaceutical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
